About Us
Our mission: Empowering healthcare with nanobodies, we're transforming diagnostics. From centralized labs to point-of-care, we pioneer swift, precise tools for better patient outcomes and the future of healthcare.
Nanobodies: Pioneering a Scientific Triumph
At Nanost Inc., we are at the forefront of a scientific revolution, where the convergence of science and innovation is shaping the future of diagnostics. Rooted in the scientific corridors of German laboratories, our story unfolds in the pursuit of precision amidst the complexities of Parkinson's disease. Faced with the intricate task of discerning alpha-synuclein aggregation in a transgenic model and distinguishing between human and mouse alpha-synuclein, our founder encountered nanobodies as a practical alternative. Recognizing their transformative potential, we embraced nanobodies—a departure from conventional monoclonal antibodies. In a pivotal moment within the lab, nanobodies were bioengineered for seamless integration with ELISA and other Point-of-Care (PoC) diagnostics. These small, single-domain proteins, sourced from camelids, emerged not just as a cost-effective solution but as a dynamic force propelling diagnostics into a new era of precision and efficiency.
Join us as we embark on this extraordinary journey, where nanobodies are poised to transform the landscape of healthcare. With unwavering dedication and a relentless pursuit of innovation, we are shaping the future of diagnostics, one nanobody at a time.
Dr. Norelle Wildburger: A Visionary in Biotech Innovation
Dr. Norelle Wildburger stands at the forefront of biotech innovation, bringing a wealth of expertise and a passion for advancing diagnostic solutions for neurological disorders. Currently serving as the Senior Director of Medical and Scientific Affairs at SYNAPS Dx, a leading biotech company, Dr. Wildburger boasts over 8 years of seasoned experience across Academia, CROs, BioPharma R&D across multiple therapeutic areas, consulting, and Biotech.
Dr. Wildburger’s journey reflects her dynamic capabilities, combining strategic expertise in mass spectrometry across translational, pre-clinical, and clinical research. Passionate about driving Precision Neurology, she brings creativity and enthusiasm to a matrixed global organization, contributing to 2 patents, 24 publications, 6 invited oral presentations, and securing over $900K in grant funding as a postdoc. She excels in servicing five departments with strong communication skills, showcasing industry knowledge in Neurology/Neuroscience Diagnostics and Biomarkers within the Biotech and Life Science sectors. Her affiliations extend to BioPharma, Regulatory, Technology Assessment, and Performance Optimization in CROs.
Passionate about fostering innovation and excellence within the biotech industry, Dr. Wildburger leverages her deep expertise in neuroscience, data analysis, biochemistry, and scientific writing to make a positive impact on people's lives. With a collaborative spirit and an unwavering commitment to advancing healthcare solutions, Dr. Wildburger stands as a visionary leader, shaping the future of biotech with her dedication to excellence and positive societal impact.
Collaborators
Maryland Tech Council VMS helps build Maryland-based companies, educate company founders and c-suite executives; attract capital; create new jobs and build the ecosystem for the Maryland technology and life sciences community.
Since 1964, SCORE has helped more than 11 million entrepreneurs start, grow or successfully exit a business.
SCORE is a 501(c)(3) nonprofit organization and a resource partner of the U.S. Small Business Administration (SBA).
Nanost Inc. is represented by Dr. Oliver Scholz. In addition to Nanost Inc., he serves global companies and numerous small and medium-sized businesses, start-ups, and individual inventors at Hansepatent.